Shares of Wockhardt Ltd. surged 18.80% to a near two-year high on Monday, as it successfully completed phase-3 pneumonia study of macrolide antibiotic Nafithromycin.
The study result showed that a short course of three-day treatment with Nafithromycin is as effective as seven-day therapy with Moxifloxacin.
Nafithromycin or Wockhardt NCE, WCK 4873 was comparatively evaluated in a multi-centre double blind phase-3 pneumonia study, employing the last-line respiratory antibiotic Moxifloxacin, an exchange filing said.
Shares of the company rose 18.8%, the most since Jan. 17, 2022, before paring gains to trade 15.48% higher at 12:42 p.m. This compares to a 0.02% advance in the NSE Nifty 50.
The stock has risen 74.67% year-to-date. Total traded volume so far in the day stood at 3.6 times its 30-day average. The relative strength index was at 76.22.
RECOMMENDED FOR YOU
Wockhardt Eyes ‘Healthy Bottom Line’ In Coming Quarters Amid US Tariff Concerns
Aug 12, 2025
Wockhardt Group Does Not Expect Much Impact From US Tariffs
Aug 11, 2025
Wockhardt Q1 Results: Loss Widens To Rs 108 Crore
Aug 08, 2025
Regaal Resources' IPO To Open On Aug 12; Sets Price Band At Rs 96-102 Per Share
Aug 07, 2025
POPULAR